# Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

> **NCT00083967** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 23 (actual)

## Conditions studied

- Retinal Detachment

## Interventions

- **DRUG:** denufosol tetrasodium (INS37217) Intravitreal Injection

## Key facts

- **NCT ID:** NCT00083967
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083967, "Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00083967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*